



12

Bibliografía

1. Breast Cancer Incidence and Mortality Worldwide in 2008. Summary Disponible en : <http://globocan.iarc.fr/factsheets/>
2. II Plan Integral de Oncología de Andalucía: 2007-2012. Consejería de Salud. Sevilla, 2007.
3. Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. *Ann Oncol.* 2008;19(6):1187-94.
4. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. *Ann Oncol.* 2008; 19(5):1009-18.
5. La situación del cáncer en España. Área de epidemiología ambiental y cáncer. Centro Nacional de Epidemiología Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Centro de publicaciones. Madrid. 2005. Disponible en: <http://cne.isciii.es/morta/>.
6. Proceso Asistencial Integrado Cáncer de Mama. Detección Precoz del Cáncer de Mama. 2ª Edición. Consejería de Salud. Sevilla, 2005.
7. Perry N, Broeders M, De Wolf C, Törnberg S, Holland R, Von Karsa L. European Guidelines for Quality Assurance In Breast Cancer Screening And Diagnosis. Luxembourg. Office for Official Publications of the European Communities. European Communities 2006. ISBN 92-79-01258-4.
8. C. K. Osborne; Monica Morrow; Marc E. Lippman; Jay R. Harris. *Diseases of the Breast.* 3ª Edición. Lippincott Williams & Wilkins. 2004
9. BI-RADS. Atlas de diagnóstico por la imagen de mama. American Collage of Radiology. 2006. SERAM. ISBN: 8461109112.
10. Dotor Gracia M, Fernández Garcia E, Álvarez Benito M. et al. Consejería de Salud. Guía de Diseño y Mejora Continua de Procesos Asistenciales Integrados. 2ª Edición. Sevilla. Junta de Andalucía, 2009.
11. http://www.juntadeandalucia.es/agenciadecalidadsanitaria/observatorioseguridadpaciente/gestor/sites/PortalObservatorio/es/menu/practicaseguras/practicaseguras_en_Cirugia_y_Anestesia. (Acceso 17 julio 2010)
12. LEY 41/2002. de 14 de noviembre, básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica.
13. OncoGuía del consejo y asesoramiento genéticos en el cáncer hereditario. Versión breve para la aplicación en la práctica clínica. Barcelona: Agència d'Avaluació de Tecnologia i Recerca Mèdiques. CatSalut. Departament de Salut. Generalitat de Catalunya. Junio 2006 (OG01/2006)
14. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. V.1.2007
15. Genetics of breast and ovarian cancer (PDQ(R)). National Cancer Institute. Health Professional version. 2008. U.S. National Institutes of Health. www.cancer.gov.
16. Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. National Institute for Health and Clinical Excellence (NICE) clinical guideline 41. October 2006.
17. Consentimientos Informados Consejería de Salud Junta de Andalucía. Disponible en: http://www.junta-deandalucia.es/salud/channels/temas/temas_es/C_6_NUESTRO_COMPROMISO_POR_LA_CALIDAD/C_11_Formularios_Consentimiento_Informado/inicio_formularios_consentimiento (Acceso 17 de Julio de 2010).

18. NCCN. Breast cancer guidelines 2011
19. New Zealand Guideline Group. 2009. Management of early breast cancer. Evidence-based Best Practice Guidelines. Wellington: New Zealand Guidelines Group.
20. BOJA 30 mayo 2003. Decreto 127/2003 de 13 de mayo por el que se establece el ejercicio del derecho a la segunda opinión médica en el Sistema Sanitario Público de Andalucía. BOJA 173 de 3 de septiembre de 2004. Orden 24 de agosto de 2004, por el que se desarrolla el Decreto 127/2003 de 13 de mayo por el que se establece el ejercicio del derecho a la segunda opinión médica en el Sistema Sanitario Público de Andalucía.
21. Alternativas de tratamiento Para el cáncer de mama ¿Qué opción prefiero?. Dirección General de Calidad, Investigación y Gestión del Conocimiento. Consejería de Salud de la Junta de Andalucía. 2006.
22. Moorhead S, Johnson M, Clasificación de Resultados Enfermeros (NOC), Cuarta Edición. Elsevier España. Barcelona 2009.
23. Bulechek GM, Butcher HK, Mcloskey Dochterman J. Clasificación de intervenciones de enfermería (NIC). Quinta Edición. Elsevier Mosby. Barcelona. 2009
24. TNM classification, AJCC (American Joint Committee on Cancer) Staging Manual, 7th edition. 2010.
25. Bermejo Pérez MJ, Márquez Calderón S. Efectividad de la cirugía profiláctica, la quimioprevención y la vigilancia intensiva en mujeres portadoras de mutaciones en los genes BRCA1 y 2. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias de Andalucía; 2010.
26. Resonancia magnética para el diagnóstico del cáncer de mama. Revisión sistemática y evaluación económica. Juan Javier Cerezo Espinosa de los Monteros, Roman Villegas Portero.- Sevilla. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía; Madrid: Ministerio de Sanidad y Consumo,2008
27. Rosselli del Turco M, Ponti A, Bick U et al. Quality indicators in breast cancer care. 2010, 46: 2344-2356
28. Recomendaciones en el manejo diagnóstico de lesiones mamarias. Consejería de Salud . Sevilla, 2003
29. Oncoplastic surgery: the evolution of breast cancer treatment. De Lorenzi F. Breast J. 2010. Sep-Oct; 16 Suppl 1: S 20-1. doi: 10.1111/j. 524-4741.2010.00997.x.
30. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347(16):1233–41.
31. Veronesi U, Saccozzi R, Vecchio Del, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305(1):6–11.
32. Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up. J Clin Oncol 1996;14:1558.
33. Mirsky D, O'Brien SE, McCreedy DR, et al. Surgical management of early stage invasive breast cancer (Stage I and II). Cancer Prevention & Control 1997;1:10-7.
34. Van Dongen J, Bartelink H, Fentiman J, et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM Stage I and II breast cancer. Eur J Cancer 1992;28:801-5.
35. Van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial

comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. *J Natl Cancer Inst* 2000;92: 1143-50.

36. Scottish Intercollegiate Guidelines Network. Management of breast cancer on women. A National Clinical Guideline. December 2005.

37. Blichert-Toft M, Rose C, Anderson JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy. *J Natl Cancer Inst Monogr* 1992;11:19-25.

38. Morris AD, Morris RD, Wilson JF, et al. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. *Cancer J Sci Am* 1997;3:6-12.

39. Morris AD, Arriagada R, Ancukiewicz M, et al. When is survival a cure in early stage breast cancer? Twenty year follow-up from 3 randomized trials [abstract]. *Int J Radiat Oncol Biol Phys* 1998;42(Suppl.1):182.

40. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer. *CMAJ* 1998;158:S15-21.

41. National Health and Medical Research Council Breast Cancer Centre. Clinical Practice Guidelines for the Management of Early Breast Cancer. Available at: <http://www.nbcc.org.au/pages/info/resource/nbccpubs/clinprof/contents.htm>. Accessed January 4, 2000.

42. Irwig L, Bennetts A. Quality of life after breast conservation or mastectomy: a systematic review. *Austr NZ J Surg* 1997;67:750-4.

43. Moyer A. Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. *Health Psych* 1997;16:284-98.

44. Curran D, van Dongen JP, Aaronson NK, Kiebert G, Fentiman IS, Mignolet F, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Cooperative Group (BCCG). *Eur J Cancer*. 1998;34(3):307-14.

45. Surgical Management of Early-Stage Invasive Breast Cancer. Practice Guideline Report #1-1 Version 2.2003. A cancer care Ontario Program.

46. R. Nadeem, L. S. Chaiga, O. Harris, et al. Occult breast lesions: A comparison between radioguided occult lesion localisation (ROLL) vs. wire-guided lumpectomy (WGL). *The Breast* (2005) 14, 283-289.

47. A. Luini, S. Zurrada, G. Paganelli, et al. Comparison of radioguided excision with wire localization of occult breast lesions. *British Journal of Surgery* 1999, 86, 522-525.

48. R. S. Rampaul, M. Bagnall, H. Burrell, et al. Randomized clinical trial comparing radioisotope occult lesion localization and wire-guided excision for biopsy of occult breast lesions. *British Journal of Surgery* 2004, 91: 1575-1577.

49. Surgical guidelines for the management of breast cancer. Association of Breast Surgery at BASO. 2009. *EJSO the Journal of Cancer Surgery*.

50. Margoless R. Surgical considerations in selecting local therapy. *J Natl Cancer Inst Monogr* 1992;11:41-8.

51. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomized trial - S6. *Eur J Cancer* 1994;30:645-5.

52. Fisher B, Brown A, Mamounas E, et al.

Effect of preoperative chemotherapy of local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol* 1997;15:2483-93.

53. Van der Hage JA, van de Velde CJ, Juien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. *J Clin Oncol* 2001;19:4224-37.

54. Mamounas EP, Fisher B. Role of preoperative systemic therapy for operable breast cancer. In: Perry MC, ed. *ASCO Educational Book*. American Society of Clinical Oncology; 2001:516-23.

55. El-Didi MH, Moneer MM, Khaled HM, et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. *Surgery Today* 2000; 30:249-54.

56. Veronesi U, Saccozzi R, Del Vecchio M et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. *N Engl J Med*. 1981; 305: 6-11.

57. Fisher B, Redmond C, Poisson R et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med*. 1989; 320: 822-8.

58. Bijker N, Peterse J, Duchateau L et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer trial 10853. *J Clin Oncol*. 2001;19:2263-2271.

59. Chan KC, Knox WF, Sinha G, Gandhi A, Barr L, Baildam AD, Bundred NJ. Extent of excision margin width required in breast

conserving surgery for ductal carcinoma in situ. *Cancer*. 2001;91:9-16.

60. Gentilini O, Intra M, Gandini S, Peruzzotti G, Winnikow E, Luini A, Veronesi P, Galimberti V, Goldhirsch A, Veronesi U. Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. Role of surgical margins on outcome. *J Surg Oncol*. 2006;94:375-379.

61. Sahoo S, Recant WM, Jaskowiak N, Tong L, Heimann R. Defining negative margins in DCIS patients treated with breast conservation therapy: the University of Chicago experience. *The Breast Journal*. 2005;11:242-247.

62. Kunos C, Latson L, Overmoyer B, Silverman P, Shenk R, Kynsella t, Lyons J. Breast conservation surgery achieving \geq 2mm tumor-free margins results in decreased local-regional recurrence rates. *The Breast journal*. 2006;12:28-36.

63. Luini A, Rososchansky J, Gatti G, Zurrida S, Caldarella P, Viale G, Rosali Dos Santos G, Frasson A. The surgical margin status after breast-conserving surgery: discussion of an open issue. *Breast Cancer Res Treat*. 2009;113(2):397-402.

64. Leong C, Boyages J, Jayasinghe UW, Bilous M, Ung O, Chua B, Salisbury E, Wong AY. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma. *Cancer*.2004;100(9):1823-1832.

65. Kamoike Y, Akiyama F, Lino Y, Ikeda T, Akasi-Tanaka S, Oshumi S et al. Ipsilateral breast tumor recurrence after breast-conserving treatment for early breast cancer. *Cancer*. 2006; 106:35-41.

66. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Breast cancer. v.1.2009. Disponible en: http://nccn.org/professionals/physician_gls/PDF/breast.pdf.

67. Ottesen GL, Graversen HP, Blichert-Toft M, et al. Carcinoma in situ of the female breast: 10 year follow-up results of a prospective nationwide study. *Breast Cancer Res Treat.* 2000; 62: 197-210.
68. Fisher ER, Costantino JP, Fisher B, et al. Pathologic finding from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: five-years observations concerning lobular carcinoma in situ. *Cancer.* 1996; 78: 1403-1416.
69. National Cancer Institute. Breast Cancer Treatment. Disponible en: <http://www.cancer.gov/espanol/pdq/tratamiento/seno/HealthProfessional/page6>.
70. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. *J Natl Compr Canc Netw.* 2006; 4: 511-522.
71. Martínez Messeguer L, Ribeiro González M. Carcinoma In situ de mama. En: Sierra García A, Piñeiro Madrona A, Illana Moreno J editores. *Cirugía de la Mama.* Madrid: Arán Ediciones; 2006; p. 245-249.
72. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: finding from the National Surgical Adjuvant Breast and Bowel Project B-17. *J Clin Oncol.* 1998; 16(2): 441-452.
73. Fisher DE, Schinitt SJ, Christian R, et al. Chest wall recurrence of ductal carcinoma in situ of the breast after mastectomy. *Cancer.* 1993; 71: 3205-3028.
74. Fisher ER, Costantino J, Fisher B, Paleari AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. *Cancer.* 1995;75:1310-9.
75. Luini A., S. Zurrada, V. Galimberti and G. Paganelli. Radioguided Surgery of Occult Breast Lesions. *Eur J Cancer.* 1998; 34(1): 204-205.
76. Nadeem R, et al. Occult breast lesions: A comparison between radioguided occult lesion localisation (ROLL) vs. wire-guided lumpectomy (WGL). *The Breast.* 2005; 14: 283-289
77. Lagios MD. Ductal carcinoma in situ. Pathology and treatment. *Surg Clin North Am.* 1990;70: 853-71.
78. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. *J Clin Oncol* 2009;27:1615-1620
79. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. *Am J Surg.* 2003; 186: 337-343.
80. Song J., Gadd M., Gelman R. et al. Wide excision alone for ductal carcinoma in situ of the breast. Proceedings of the 2003 San Antonio Breast Cancer Symposium. December 2003. Abstract 15. URL disponible en; <http://patient.cancerconsultants.com/>.
81. Burnstein HJ, Polyak K, Wong JS, Lester Sc, Kaelin CM. Ductal carcinoma in situ of the breast. *N Engl J Med.* 2004;350:1430-41.
82. Julián TB, Land SR, Fourchette V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? *Ann Surg Oncol* 2007;14:2202-2208.
83. Michaelson JS, Silverstein M, Wyatt J. Predicting the survival of patients with breast carcinoma using tumor size. *Cancer* 2002; 95: 713-723.
84. Mabry H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? *Ann Surg Oncol* 2007;14:2209-2214.

- noma in situ? *Am J Surg*. 2006; 192: 455-457.
85. Silva O E, Zurrída S. Eds. *Breast Cancer. A Practical Guide*. Third edition. Elsevier editorial. London 2005.
86. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ et al. Fluodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. *BJS* 2006; 93: 707-712.
87. Chua B. Outcomes of sentinel node biopsy for breast cancer in British Columbia 1996-2001. *Am J Surg* 2003; 185:118-26.
88. Vidal-Sicart S, Paredes P, Zano G, Pahisa J, Martínez-Roma S, Caparros X, Vilalta A, Rull R, Pons F. Added Value of Intraoperative Real-Time Imaging in Searches for Difficult-to-Locate Sentinel Nodes. *J Nucl Med* 2010; 51:1219-1225.
89. NCCN Clinical Practice Guidelines in Oncology. *Breast Cancer v.2009*
90. Whelan T, Clark R, Roberts R et al. Ipsilateral breast tumour recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. *Int J Radiat Oncol Biol Phys* 1994; 30: 11-16.
91. Haffty BG, Reiss M, Beinfeld M et al. Ipsilateral breast tumour recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. *J Clin Oncol* 1996; 14: 52-57.
92. Voogd AC, van Tienhoven G, Peterse HL et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study Group on Local Recurrence after Breast Conservation (BORST). *Cáncer* 1999; 85: 437-446.
93. Veronesi U, Marubini E, Del Vecchio M et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. *J Natl Cancer Inst* 1995; 87: 19-27.
94. Wapnir IL, Anderson SJ, Mamounas EP et al. Prognosis after ipsilateral breast tumour recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. *J Clin Oncol* 2006; 24: 2028-2037.
95. Shikama N, Sekiguchi K, Nakamura N. Management of locoregional recurrence of breast cancer. *Breast Cancer*. 2010.
96. Willner J, Kiricuta IC, Kölbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. *Int J Radiat Oncol Biol Phys*. 1997 Mar 1; 37(4):853-63.
97. Kurtz JM, Jacquemier J, Amalric R et al. Is breast conservation after local recurrence feasible? *Eur J Cancer* 1991; 27: 240-244.
98. Salvadori B, Marubini E, Miceli R et al. Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. *Br J Surg* 1999; 86: 84-87.
99. Recht A, Schnitt SJ, Connolly JL et al. Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. *Int J Radiat Oncol Biol Phys* 1989; 16: 3-9.
100. Maulard C, Housset M, Brunel P et al. Use of perioperative or split-course interstitial brachytherapy techniques for salvage irradiation of isolated local recurrences after conservative management of breast cancer. *Am J Clin Oncol* 1995; 18: 348-352.
101. Resch A, Fellner C, Mock U et al. Locally recurrent breast cancer: pulse dose rate brachytherapy for repeat irradiation following lumpectomy—a second chance to preserve the breast. *Radiology* 2002; 225: 713-718.

102. Kuerer HM, Arthur DW, Haffty BG et al. Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence. The potential role of partial breast irradiation. *Cancer* 2004; 100: 2269-2280.
103. O. Gentilini, E. Botteri, N. Rotmensz, B. Santillo, N. Peradze, R. C. Saihum, M. Intra, A. Luini, V. Galimberti, A. Goldhirsch, U. Veronesi. When can a second conservative approach be considered for ipsilateral breast tumour recurrence?. *Ann Oncol* 2007;18: 468-472.
104. Abner AL, Recht A, Eberlein T et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. *J Clin Oncol* 1993; 11: 44-48.
105. Leonard R, Hardy J, van Tienhoven G, Houston S, Simmonds P, David M, Mansi J. Randomized, double-blind, placebo-controlled, multicenter trial of 6% mitofosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. *J Clin Oncol*. 2001 Nov 1; 19(21):4150-9.
106. Van del Ploeg et al. Axillary recurrence after a tumour negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. *Eur J Surg Oncol (EJSO)* 2008; 34(12): 1277-84.
107. Bergkvist et al. Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish multicenter cohort study. *Ann Surg* 2008; 247:150-6)
108. Fujiwara M, Mizukami T, Suzuki A, Fukamizu H. Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: preliminary experience. *J Plast Reconstr Aesthet Surg*. 2009 Oct;62(10):e373-8. Epub 2008 Jun 16.
109. Acea B. Técnicas Oncoplásticas para el manejo de tumores centrales de mama. *Cir. Esp.* 2009; 85:14-0.
110. Desouches C., Aharoni C., Magalon G. Analyse descriptive des différents implants mammaires disponibles sur le marché européen en 2005 *Ann. Chir. Plast.* 2005 ; 50 : 694-701.
111. Yamada A. Choice of flaps for breast reconstruction *Int. J. Clin. Oncol.* 2005 ; 10 : 289-297.
112. Reconstrucción mamaria. Sociedad canadiense de Cirugía Plástica y Reparadora. <http://www.breastreconstruction.ca>.
113. Gómez Cía T. Reconstrucción mamaria. Guía de Práctica Clínica (2004). Hospital Universitario Virgen del Rocío.
114. Sanchez-Guerrero J., Colditz G.A., Karlson E.W., Hunter D.J., Speizer F.E., Liang M.H. Silicone breast implants and the risk of connective-tissue diseases and symptoms *N. Engl. J. Med.* 1995 ; 332 : 1666-1670.
115. Schusterman M.A., Kroll S.S., Miller M.J., Reece G.P., Baldwin B.J., Robb G.L., y al. The free transverse rectus abdominis musculocutaneous flap for breast reconstruction: one center's experience with 211 consecutive cases *Ann. Plast. Surg.* 1994 ; 32 : 234-242.
116. Munhoz AM, Arruda E, Montag E, Aldrighi C, Aldrighi JM, Gemperli R, Ferreira MC. Immediate Skin-Sparing Mastectomy Reconstruction with Deep Inferior Epigastric Perforator (DIEP) Flap. Technical Aspects and Outcome. (2007), *The Breast Journal*, 13: 470-478. doi: 10.1111/j.1524-4741.2007.00467.x
117. Bailey SH, Oni G, Guevara R, Wong C, Saint-Cyr M. Latissimus Dorsi Donor-Site Morbidity: The Combination of Quilting Sutures and Fibrin Sealant Reduce Length of Drain Placement and Seroma Rate. *Ann Plast Surg.* 2011 May 27.
118. Kijima Y, Yoshinaka H, Hirata M, Mizoguchi T, Ishigami S, Arima H, Nakajo A,

- Ueno S, Natsugoe S. Immediate reconstruction using a modified thoracodorsal adipofascial cutaneous flap after partial mastectomy. *Breast*. 2011 May 27
119. Munhoz AM, Montag E, Arruda E, Okada A, Brasil JA, Gemperli R, Filassi JR, Ferreira MC. Immediate locally advanced breast cancer and chest wall reconstruction: surgical planning and reconstruction strategies with extended v-y latissimus dorsi myocutaneous flap. *Plast Reconstr Surg*. 2011 Jun;127(6):2186-97.
120. Minabe T, Harii K, Imanishi N. Latissimus dorsi flaps oriented on the lateral intercostal artery perforators: anatomical study and application in autologous breast reconstruction. *J Plast Surg Hand Surg*. 2011 Apr;45(2):58-65.
121. Dejode M, Bordes V, Jaffré I, Classe JM, Dravet F. Oncologic, functional, and aesthetics results; evaluation of the quality of life after latissimus dorsi flap breast reconstruction. About a retrospective series of 450 patients. *Ann Chir Plast Esthet*. 2011 Mar 28.
122. Dini M, Quercioli F, Mori A, Agostini T. Expanding the Indications for Latissimus Dorsi Musculocutaneous Flap in Totally Autologous Breast Reconstruction: The Extended Variant. *Ann Surg Oncol*. 2010 Dec 21.
123. Van Geel AN, Lans TE, Haen R, Tjong Joe Wai R, Menke-Pluijmers MB. Partial mastectomy and m. latissimus dorsi reconstruction for radiation-induced fibrosis after breast-conserving cancer therapy. *World J Surg*. 2011 Mar;35(3):568-72.
124. Garusi C, Lohsiriwat V, Brenelli F, Galimberti VE, De Lorenzi F, Rietjens M, Rossetto F, Petit JY. The value of latissimus dorsi flap with implant reconstruction for total mastectomy after conservative breast cancer surgery recurrence. *Breast*. 2011 Apr;20(2):141-4.
125. Veronesi U, Banfi A, Salvatore B et al. Breast conservation is the treatment of choice in small breast cancer: long term results of a randomized trial. *Eur J Cancer* 1990; 26:668-70
126. Acea B. Técnicas oncoplásticas para el manejo de tumores centrales de mama . *Cir Esp*. 2009;85:14-9.
127. Acea B. Cirugía sin cicatrices visibles en el tratamiento del cáncer de mama. *Cir Esp*. 2010;87:210-7.
128. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. *Lancet* 2005; 365:1687–1717.
129. Del Barco S, Ciruelos E, Tusquest I. et al.(2010) SEOM clinical guidelines for the treatment of early breast cancer. *Clin Transl Oncol* 12:711-718
130. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Ovarian ablation in early breast cancer: overview of the randomized trials. *Lancet* 1996; 348:1189–1196
131. Albanell J, Álvarez I, Barnadas A et al.). Consenso en el tratamiento hormonal adyuvante del cáncer de mama de pacientes premenopáusicas. *Curr Opin Oncol* 2007; 19:S25–S35
132. Buzdar A, on behalf of the ATAC Trialists' Group. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in post-menopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. *San Antonio Breast Cancer Symposium* 2002. Abstract 1
133. The Breast International Group (BIG) Collaborative Group. A comparison of Letrozole and Tamoxifen in post-menopausal women with early breast cancer. *N Engl J Med* 2005; 353:2747-57

134. Coombes RC, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 2004; 350:1140-2
135. Goss PE, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med* 2003; 349:1793-802.
136. Mamounas, JJ, et al. Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. *J Clin Oncol*. 2008;26(12):1965-71
137. Levine MN, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1998;16(8):2651-58.
138. Henderson IC; Berry DA; Demetri GD EY AL. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. *J Clin Oncol*, 2003; 15;21(6):976-83.
139. Sparano J.A., M. Wang and S. Martino et al., Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199, *Proc ASCO* 25 (18S) 2007, p. 516.
140. Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. *J Clin Oncol* 2006; 24:5381-5387
141. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. *N Engl J Med* 2005; 352:2302-2313
142. Viani GA, Afonso SL, Stefano EJ et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. *BMC Cancer* 2007; 7:153
143. Mamounas EP, Wang J, Bryant J, et al. Patterns of loco-regional failure (LRF) in patients receiving neoadjuvant chemotherapy (NC): results from NSABP B-18. *Breast Cancer Res Treat* 82 (Suppl 1): 2003; A-35, S17
144. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. *J Natl Cancer Inst* 2005; 97:188-195
145. Jacobson et al. American Society of clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards. *J Clin Oncol* . 2009; 32:5469-75.
146. Documento de consenso para la prevención de errores de medicación en quimioterapia. GEDEFO. [consultado 23/06/2010]. Disponible en <http://www.sefh.es/gedefo/errores.php>.
147. Estándares de calidad de los Servicios de Farmacia Oncológica (QuapoS 4). [consultado en 23/06/2010]. Disponible en <http://www.esop.li/activities.php>
148. Greenlee RT, Murray T, Bolden S, et al: *Cancer Statistics, 2000*. *CA Cancer J Clin* 2000; 50:7.
149. Gloeckler Ries LA: Rates. In: Harris A, Edwards BK, Blot WJ, et al (eds): *Cancer Rates and Risks*, 4th ed, pp 42-43. Bethesda, National Institutes of Health Publication No 96-691, 1996.
150. Ragaz J, Olivetto IA, Spinelli JJ, et al: Locoregional radiation therapy in patients

with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. *J Natl Cancer Inst* 97:116-126, 2005

151. Whelan TJ, Julian J, Wright J, et al.: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. *Journal of Clinical Oncology* 18(6): 1220-1229, 2000.

152. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. *Radiother. Oncol.*2007;82:247-53.

153. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;366:2087–2106.

154. Estudio sobre eficacia, efectividad y eficiencia de IMRT: Javier Caballero Villaraso, Sergio Márquez Peláez, Belen Corbacho Martín, Amalia Palacios Eito. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, 2010.

155. Evidence based radiation oncology; Breast cancer. Poortmans P. *Radiotherapy and Oncology* 84 (2007) 84-101

156. Breast Cancer in Women. Scottish Intercollegiate Guidelines Network. Last modified December 2005. SIGN publication no. 84 (QRG) <http://www.sign.ac.uk/pdf/sign84.pdf>

157. Cancer.gov - Breast Cancer (PDQ®): Treatment

158. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. *Cancer* 1999;85:616-28

159. Bijker N, Meijnen P, Peterse JL, et al. Breast conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *J Clin Oncol* 2006;24:3381–7.

160. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. *Cancer* 1999;86:429–38.

161. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized controlled trial. *Lancet* 2003;362:95–102.

162. Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson L-G, Sandelin K, et al. Absolute risk reductions for local recurrence after post operative radiotherapy after sector resection for ductal carcinoma in situ. *Journal of Clinical Oncology* 2008;26(8):1247–52.

163. Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. *Lancet Oncol* 2006;7:652–6.

164. Silverstein MJ. An argument against routine use of radiotherapy for ductal carcinoma in situ. *Oncology (Huntingt)* 2004; 17: 1511-1533

165. Hughes L, Wang M, Page D et al. Five year results of intergroup study E5194: Local excision alone (without radiation treatment) for selected patients with ductal carcinoma in situ (DCIS). *Breast Cancer Res Treat* 2006;100(suppl 1):S15.

166. Fisher B, Bauer M, Margolese R, Pois-

- son R, Pilch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. *N Engl J Med* 1985;312(11):665-73.
167. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med* 1995;333(22):1456-61
168. Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabár L, Nordgren H, et al. 10-year results after sector resection with or without postoperative radiotherapy for stage 1 breast cancer: a randomized trial. *J Clin Oncol* 1999;17(8):2326-33.
169. Clark RM, McCulloch PB, Levine MN, Lipa M, Wilkinson RH, Mahoney LJ, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. *J Natl Cancer Inst* 1992;84(9):683-9.
170. Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. *Lancet* 1996;348:708-13.
171. Holli K, Saaristo R, Isola J, Joensuu H, Hakama M. Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. *Br J Cancer* 2001;84(2):164-9.
172. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 2000;355:1757-70.
173. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. *J Clin Oncol* 2006;24:2268-2275.
174. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Loco-regional recurrence after mastectomy in high-risk breast cancer -- risk and prognosis: an analysis of patients from the DBCG 82 b&c randomization trials. *Radiother Oncol* 2006;79:147-155
175. Breast-Conserving Surgery With or Without Radiotherapy: Pooled-Analysis for Risks of Ipsilateral Breast Tumor Recurrence and Mortality. Vinh-Hung V, Verschraegen C.: *J Natl C Inst* 96, 2:115-121, 2004
176. REAL DECRETO 1566/1998, de 17 de julio, por el que se establecen los criterios de calidad en radioterapia. BOE número 206 de 28/8/1998, páginas 29383 a 29394 (12 págs.). BOE-A-1998-20644
177. Kim E, Brady LW. Rectal Cancer. In: J.J. Lu, W. Brady (Eds.). *Decision Making in Radiation Oncology Volume 1*. Springer-Verlag Berlin Heidelberg; 2011. ISBN: 978-3-642-12462-4.
178. Grann A, McCormick B, Chabner ES, Gollamudi SV, Schupak KD, Mychalczak BR, Heerdt AS, Merchant TE, Hunt MA. Pro-ne breast radiotherapy in early-stage breast cancer: a preliminary analysis. *Int J Radiat Oncol Biol Phys* 2000; 47:319-325) (Campaña F, Kirova YM, Rosenwald JC, Dendale R, Vilcoq JR, Dreyfus H, Fourquet A. Breast radiotherapy in the lateral decubitus position: A technique to prevent lung and heart irradiation. *Int J Radiat Oncol Biol Phys* 2005; 61: 1348-1354
179. Kirova YM, Castro Pena P, Hijal T,

- Fournier-Bidoz N, Laki F, Sigal-Zafrani B, Dendale R, Bollet MA, Campana F, Fourquet A. Improving the definition of tumor bed boost with the use of surgical clips and image registration in breast cancer patients. *Int J Radiat Oncol Biol Phys.* 2010 Dec 1;78(5):1352-5.
180. Kirova YM. Recent advances in breast cancer radiotherapy: Evolution or revolution, or how to decrease cardiac toxicity? *World J Radiol.* 2010 Mar 28;2(3):103-8.
181. Vicini FA, Sharpe M, Kestin L, Martinez A, Mitchell CK, Wallace MF, Matter R, Wong J. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 2002; 54: 1336-1344
182. Avellanet Viladomat M, González Viejo MA, Condón Huerta MJ, Sáenz Guerrero A. Linfedema secundario a linfadenectomía axilar: concepto y valoración. *Rehabilitación (Madr)* 2003;37:215-21
183. International consensus. Lymphoedema framework. Best practice for the management of lymphoedema. London. MEP Ltd.2006.
184. Lauridsen MC, Christiansen P, Hessov IB. The effect of physiotherapy on shoulder function in patients surgically treated for breast cancer: A randomized study. *Acta oncológica* 2005; 44: 449-457
185. Blovinqvist L, Strak B . Evaluation of the arm and shoulder and strength after modified radical mastectomy and radiotherapy. *Acta oncológica* 2004; 43; 280-283.
186. Rietman JS, Dijkstra PU, Geertzen JH, Baas P, De Vries J, Dolsma WV, Groothoff JW, Eisma WH, Hoekstra HJ. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer. *Ann Surg Oncol.* 2004 Nov;11:1018-24.
187. Gummesson C.; Ward M.; Atroshi I.; The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. Published: 18 May 2006 *BMC Musculoskeletal Disorders* 2006, 7:44
188. I.Tengrup. Arm morbidity after breast-conserving therapy for breast cancer. *Acta oncológica* 2000; 39: 393-397.
189. Versión Francesa (Francia): Bouhasira D, et al. *Pain* 2005; 114: 29-36. Versión Española (España): Pérez C, et al. EFIC 2006
190. Galván A et al. Patología Postquirúrgica del cáncer de mama. Propuesta de subproceso y desarrollo de una unidad de tratamiento rehabilitador en el contexto sanitario andaluz. *Rehabilitación* 2008; 42(1):27-33
191. Campisi C, Boccardo F, Zilli A, Maccio A, Napoli F, Ferreira Azevedo W, Fulcheri E, Taddei G. *Ann Ital Chir.* Lymphedema secondary to breast cancer treatment: possibility of diagnostic and therapeutic prevention. 2002 Sep-Oct;73(5):493-8.
192. Lecuona Navea, M.; Duo Trecet, M.L.; Etxaniz Gabilondo, M.; Rehabilitación precoz en el cáncer de mama : a propósito de 392 casos - *Rehabilitación* 1995 ; 29(2) : 72-78
193. Rehabilitación del Linfedema. Actualización y protocolo. Servicio de Medicina Física y Rehabilitación. Hospital Comarcal de Valdeorras. SERGAS. Servicio Gallego de Salud. Xunta de Galicia. Abril de 2008